Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764205 | 0.94 | NPBWR1 (0.43) | ALDH1A1LMNAMAPTSCN9AGPR119 | |
| SCHEMBL17140249 | 0.87 | ALDH1A1 (0.49) | ALDH1A1LMNAMAPTGPR119DPP4 | |
| SCHEMBL2088384 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119USP30 | |
| SCHEMBL28694553 | 0.82 | NPBWR1 (0.44) | ALDH1A1LMNAMAPTEPHX2 | |
| SCHEMBL16463397 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTEPHX2DRD2 | |
| SCHEMBL31043946 | 0.81 | LMNA (0.52) | ALDH1A1LMNAMAPTSCN9AGPR119 | |
| SCHEMBL653533 | 0.81 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTSCN9AUSP30 | |
| SCHEMBL28572066 | 0.81 | USP30 (0.50) | ALDH1A1MAPTSCN9AUSP30EPHX2 | |
| SCHEMBL28572069 | 0.81 | USP30 (0.50) | ALDH1A1MAPTSCN9AUSP30EPHX2 | |
| SCHEMBL28577434 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SCN9AGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | ALDH1A1 1970/4885LMNA 2773/4885MAPT 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.